Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock Published in Intensive Care Medicine, Inotrem's results highlight the pivotal role of the soluble TREM-1 biomarker in identifying high-risk septic shock patients and guiding targeted treatment with nangibotide. Paris, July 23rd, 2025 – Inotrem, a clinical-stage biotechnology company specialized in immunotherapy for […]